我要投票 莎普爱思在滴眼液行业中的票数:454
· 外 推 电 报 ·
2025-08-18 21:23:41 星期一

【莎普爱思是哪个国家的品牌?】

莎普爱思是什么牌子?「莎普爱思」是 浙江莎普爱思药业股份有限公司 旗下著名品牌。该品牌发源于浙江,由创始人陈德康在2000-07-17期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力莎普爱思品牌出海!将品牌入驻外推网,定制莎普爱思品牌推广信息,可以显著提高莎普爱思产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

公司自1978年建厂以来,经历了从“国营浙江平湖制药厂”转制成“浙江平湖制药厂(股份合作)”到“浙江平湖莎普爱思制药有限公司”,再到“浙江莎普爱思制药有限公司”,最终于2008年12月15日更名为“浙江莎普爱思药业股份有限公司”,目前注册资金为4900万元人民币。

公司作为一家专业从事药品研发、生产、经营的综合性制药企业,先后被列为“国家高新技术企业”、“浙江省百家最具投资价值企业”、“浙江省千家成长之星企业”、“浙江省级企业技术中心”、“省级高新技术研究开发中心”、“浙江省标准创新型企业”、“嘉兴市重点企业技术创新团队”、“院士专家工作站”等多项荣誉称号。

目前公司拥有大容量注射剂(玻璃瓶、塑料瓶和多层共挤膜袋)、口服溶液剂、滴眼剂、片剂(含头孢菌素类)、硬胶囊剂(含头孢菌素类)、栓剂、颗粒剂(含头孢菌素类)、干混悬剂(含头孢菌素类)、冲洗剂共10个剂型,近百种规格的产品批准文号。抗白内障新药“莎普爱思”滴眼液和抗青光眼新药“达靓”滴眼液被列入“国家火炬计划项目”。“莎普爱思”滴眼液还荣获国家重点科技攻关项目、国家重点新产品、浙江省名牌产品等多个称号,是国内第一个国家二类眼科专科新药。

几十年来,公司凭着优质的产品,良好的信誉,在市场竞争日益激烈的情况下,赢得了市场,产品销往全国各地,取得了良好的经济效益。近年来公司的产品销量与销售额都呈现出逐年增涨的态势,是平湖市重点扶持的股改上市企业。

在竞争激烈的医药市场中,我公司始终坚持科技兴业、加强管理、保证质量,不断推出各种自主研发的新产品。公司秉承“科技创新、求是进取、优质高效、和谐健康”的企业精神,不断寻求创新与突破,逐步使公司成为现代化、高科技制药企业。

莎普爱思的未来将坚持以市场为导向,发展为主题,科技创新为核心。以保护和增进人民健康、提高人民福祉为目标。我们确信莎普爱思的无限“关爱”会遍及中国,走向世界。

英文翻译:Since its establishment in 1978, the company has gone through the transformation from "state-owned Zhejiang Pinghu pharmaceutical factory" to "Zhejiang Pinghu pharmaceutical factory (joint stock cooperation)" to "Zhejiang Pinghu sapais Pharmaceutical Co., Ltd." and then to "Zhejiang sapais Pharmaceutical Co., Ltd." and finally changed its name to "Zhejiang sapais pharmaceutical Co., Ltd." on December 15, 2008, with the current registered capital of 49 million yuan RMB. As a comprehensive pharmaceutical enterprise specializing in drug R & D, production and operation, the company has been listed as "national high-tech enterprise", "one hundred enterprises with the most investment value in Zhejiang Province", "one thousand growth star enterprises in Zhejiang Province", "Zhejiang provincial enterprise technology center", "provincial high-tech research and development center", "Zhejiang standard innovation enterprise" "Jiaxing key enterprise technology innovation team", "academician expert workstation" and other honorary titles. At present, the company has 10 dosage forms of large capacity injection (glass bottles, plastic bottles and multi-layer coextrusion film bags), oral solution, eye drops, tablets (including cephalosporins), hard capsules (including cephalosporins), suppositories, granules (including cephalosporins), dry suspension (including cephalosporins), washing agents, and approval numbers of nearly 100 specifications of products. The new anti cataract drug "sapais" eye drops and the new anti glaucoma drug "Daliang" eye drops are listed in the "National Torch Program project". "Saps eye drops" also won the titles of national key scientific and technological research projects, national key new products, Zhejiang famous brand products, etc., and is the first national class II ophthalmic specialty new drug in China. In the past few decades, with its high quality products and good reputation, the company has won the market and sold its products to all parts of the country under the increasingly fierce market competition, and achieved good economic benefits. In recent years, the sales volume and sales volume of the company have been increasing year by year. It is a listed company supported by Pinghu City. In the highly competitive pharmaceutical market, our company always adheres to the development of science and technology, strengthening management, ensuring quality, and constantly launches various new products independently researched and developed. The company adheres to the enterprise spirit of "scientific and technological innovation, truth-seeking and enterprising, high-quality and efficient, harmonious and healthy", constantly seeks innovation and breakthrough, and gradually makes the company become a modern, high-tech pharmaceutical enterprise. In the future, SAPS will adhere to the market-oriented, development oriented theme and technological innovation as the core. With the goal of protecting and promoting people's health and improving people's well-being. We are sure that the infinite "love" of sapeus will spread all over China and go to the world.

本文链接: https://www.waitui.com/brand/a5a71ec58.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

北京科锐:控股股东及实际控制人拟减持不超2.83%公司股份

36氪获悉,北京科锐公告,公司控股股东北京科锐北方科技发展有限公司及实际控制人、董事长付小东计划自本次减持计划对外披露之日起15个交易日后的三个月内(即2025年9月10日至2025年12月9日),通过集中竞价或大宗交易方式减持公司股份。其中,科锐北方拟减持不超过1146.79万股,占公司总股本比例约2.11%;付小东拟减持不超过388.42万股,占公司总股本比例约0.72%。减持价格将根据减持时的市场价格确定,减持原因为科锐北方股东资金需求及付小东个人资金需求。

2小时前

景嘉微:拟2.2亿元增资诚恒微 成为其控股股东

36氪获悉,景嘉微公告,公司拟以自有资金2.2亿元参与无锡诚恒微电子有限公司增资项目,增资完成后,公司将直接持有目标公司33.59%的股权,并通过一致行动关系,合计取得目标公司64.89%的表决权,成为目标公司的控股股东。诚恒微锚定边端侧算力引擎,主营业务为边端侧AI芯片设计、研发与销售,采用Fabless经营模式,业务涵盖了集成电路设计前沿研发、芯片架构设计、配套软件开发及行业解决方案赋能,构建从技术探索到产业落地的全链条能力。

2小时前

中航沈飞:预计上半年归母净利润同比下降30%左右

36氪获悉,中航沈飞公告,预计2025年半年度实现营业收入146.28亿元左右,同比下降32.35%左右;归属于上市公司股东的净利润11.36亿元左右,同比下降29.78%左右;归属于上市公司股东的扣除非经常性损益的净利润10.74亿元左右,同比下降32.38%左右。

2小时前

隆盛科技:拟投资2亿元在重庆建设新能源汽车轻量化零部件生产基地

36氪获悉,隆盛科技公告,公司控股孙公司重庆隆盛茂茂新能源科技有限公司拟与重庆共享工业投资有限公司签署合作协议,在重庆市沙坪坝区投资建设“隆盛茂茂新能源汽车轻量化零部件生产基地项目”,项目总投资约为2亿元,主要开展新能源汽车驱动类零部件、热管理、轻量化部件等产品的生产制造。该项目将扩大公司在新能源汽车轻量化领域的产能规模,并借助区域产业集群优势提升核心竞争力和市场影响力。

2小时前

李强主持召开国务院第九次全体会议

李强强调,要进一步提升宏观政策实施效能,深入评估政策实施情况,及时回应市场关切,稳定市场预期。要抓住关键着力点做强国内大循环。持续激发消费潜力,系统清理消费领域限制性措施,加快培育壮大服务消费、新型消费等新增长点。加力扩大有效投资,发挥重大工程引领带动作用,适应需求变化更多“投资于人”、服务于民生,积极促进民间投资。纵深推进全国统一大市场建设,不断释放超大规模市场红利。采取有力措施巩固房地产市场止跌回稳态势。要在深化改革开放中增强发展动力,推进科技创新和产业创新深度融合,激发各类经营主体的创新创造活力。坚定不移扩大高水平对外开放,有序扩大自主开放和单边开放。要更大力度稳定就业保障民生,加强防灾减灾救灾和安全生产监管,确保社会大局稳定。(央视新闻)

2小时前

本页详细列出关于莎普爱思的品牌信息,含品牌所属公司介绍,莎普爱思所处行业的品牌地位及优势。
咨询